Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:GSAC OTCMKTS:NSPX OTCMKTS:NXEN NASDAQ:ONCT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGSACGelStat$0.00$0.00$0.00▼$0.00$1.50M2.96522,562 shs302,562 shsNSPXInspyr Therapeutics$0.00$0.00▼$0.07$1.47M-17.3313.19 million shs29.64 million shsNXENNexien Biopharma$0.01$0.01$0.00▼$0.05$400K-0.792,399 shsN/AONCTOncternal Therapeutics$0.53$0.53$0.53▼$7.63$1.56M1.1893,917 shsN/A The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGSACGelStat0.00%0.00%0.00%+33.33%+11.11%NSPXInspyr Therapeutics0.00%0.00%0.00%0.00%0.00%NXENNexien Biopharma0.00%0.00%0.00%-36.67%-67.61%ONCTOncternal Therapeutics0.00%0.00%0.00%0.00%-93.13%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGSACGelStatN/AN/AN/AN/AN/AN/AN/AN/ANSPXInspyr TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANXENNexien BiopharmaN/AN/AN/AN/AN/AN/AN/AN/AONCTOncternal TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGSACGelStat 0.00N/AN/AN/ANSPXInspyr Therapeutics 0.00N/AN/AN/ANXENNexien Biopharma 0.00N/AN/AN/AONCTOncternal Therapeutics 2.25Hold$10.001,798.97% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGSACGelStatN/AN/AN/AN/AN/AN/ANSPXInspyr TherapeuticsN/AN/AN/AN/A($0.07) per shareN/ANXENNexien BiopharmaN/AN/AN/AN/A($0.01) per shareN/AONCTOncternal Therapeutics$790K1.97N/AN/A$10.19 per share0.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGSACGelStatN/AN/A0.00∞N/AN/AN/AN/AN/ANSPXInspyr Therapeutics-$6.30MN/A0.00N/AN/AN/AN/A-1,354.49%N/ANXENNexien Biopharma-$240KN/A0.00∞N/AN/AN/A-4,015.59%N/AONCTOncternal Therapeutics-$39.48M-$11.69N/AN/AN/A-1,599.95%-177.58%-131.30%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGSACGelStatN/AN/AN/AN/AN/ANSPXInspyr TherapeuticsN/AN/AN/AN/AN/ANXENNexien BiopharmaN/AN/AN/AN/AN/AONCTOncternal TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGSACGelStatN/AN/AN/ANSPXInspyr TherapeuticsN/A0.090.09NXENNexien BiopharmaN/A0.020.02ONCTOncternal TherapeuticsN/A2.392.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGSACGelStatN/ANSPXInspyr Therapeutics0.02%NXENNexien BiopharmaN/AONCTOncternal Therapeutics16.05%Insider OwnershipCompanyInsider OwnershipGSACGelStat20.50%NSPXInspyr Therapeutics0.02%NXENNexien Biopharma30.60%ONCTOncternal Therapeutics11.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGSACGelStat23.74 billion2.97 billionNot OptionableNSPXInspyr Therapeutics1543.15 millionN/ANot OptionableNXENNexien Biopharma470.77 million49.12 millionNot OptionableONCTOncternal Therapeutics302.96 million2.63 millionNo DataNXEN, ONCT, GSAC, and NSPX HeadlinesRecent News About These CompaniesOncternal sells assets for up to $68m and calls it quitsJuly 1, 2025 | pharmaceutical-technology.comPROR deal: Oncternal sells cancer assets to mystery biotech for $3M, winds down operationsJuly 1, 2025 | fiercebiotech.comFOncternal Therapeutics Announces the Sale of Select Development Programs and the Wind-Down of its OperationsJuly 1, 2025 | globenewswire.comChronic Lymphocytic Leukemia Pipeline Appears Robust With 55+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightJune 17, 2025 | theglobeandmail.comMarginal Zone Lymphoma Pipeline Appears Robust With 50+ Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightMay 21, 2025 | theglobeandmail.comOncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SECMarch 7, 2025 | globenewswire.comOncternal Therapeutics (NASDAQ:ONCT) Stock, Short Interest ReportNovember 26, 2024 | benzinga.comOncternal Therapeutics Reports Q3 2024 EarningsNovember 21, 2024 | markets.businessinsider.comOncternal announces workforce reduction, executive changesNovember 17, 2024 | investing.comOncternal announces workforce reduction, executive changesNovember 17, 2024 | investing.comOncternal Therapeutics to Cut Most of Its WorkforceNovember 14, 2024 | marketwatch.comOncternal Therapeutics Faces Workforce Reduction Challenges: Potential Risks and ImplicationsNovember 9, 2024 | markets.businessinsider.comONCT-534 Produces Tolerable Safety Outcomes in Relapsed/Refractory mCRPCOctober 23, 2024 | curetoday.comCWhat’s Causing Oncternal Therapeutics Inc (ONCT) Stock’s -76.41% Drop Over the Last Six Months?October 23, 2024 | bovnews.comBOncternal Therapeutics announces updated data from Phase 1/2 study of ONCT-534October 23, 2024 | markets.businessinsider.comMetastatic Prostate Cancer Pipeline Insights, Treatment Drugs, Clinical Trials, and Companies 2024October 7, 2024 | theglobeandmail.comNorthland Securities Sticks to Its Buy Rating for Heron Therapeutics (HRTX)September 27, 2024 | markets.businessinsider.comEarlier Info on Financial Stress; Obesity and Second Cancers; Carcinogenic Condoms?September 19, 2024 | medpagetoday.comMStockWatch: Moderna’s $1.1B R&D Cut, Profitability Delay Jolt InvestorsSeptember 16, 2024 | genengnews.comGOncternal stops cancer trials and begins search for future business optionsSeptember 14, 2024 | endpts.comEMedia Sentiment Over TimeNXEN, ONCT, GSAC, and NSPX Company DescriptionsGelStat OTCMKTS:GSAC$0.0004 0.00 (0.00%) As of 07/15/2025 09:35 AM EasternGelStat Corporation, a consumer health care company, engages in the research, development, and marketing of over-the-counter and other non-prescription consumer health care products. Its products include GelStat Migraine, a patented solution used for pain relief from migraine headaches; Chews 2 Lose, an appetite suppressant gum for diet aide; All Natural Speed, an energy supplement product; and GelStat Sleep, a product for relief from sleep disorders and its associated symptoms. The company sells its products to retailers, wholesalers, specialty distributors, and catalog merchandisers both directly and through external sales brokers. GelStat Corporation was founded in 2002 and is headquartered in Palm City, Florida.Inspyr Therapeutics OTCMKTS:NSPXInspyr Therapeutics, Inc. is a pharmaceutical company, which engages in the research and development of novel therapeutics for the treatment of cancer. Its product pipeline includes Mipsagargin, a dual A2A/A2B antagonist, an A2A antagonist, an A2B antagonist, and an A2A agonist. The company was founded by Craig A. Dionne, John T. Issacs, and Samuel R. Denmeade on November 21, 2003 and is headquartered in Westlake Village, CA.Nexien Biopharma OTCMKTS:NXEN$0.0057 0.00 (0.00%) As of 07/14/2025Nexien BioPharma, Inc. focuses on the formulation, development, and commercialization of cannabinoid-based pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders, and medical conditions. The company was formerly known as Intiva BioPharma Inc. and changed its name to Nexien BioPharma, Inc. in September 2018. Nexien BioPharma, Inc. is based in Glendale, Colorado.Oncternal Therapeutics NASDAQ:ONCTOncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Tesla: 2 Plays Ahead of Next Week's Earnings Report New Catalyst Sends Joby Stock to 52-Week Highs Palantir Gets Price Hike From Wedbush Amid High Valuation Delta Air Lines Stock Rallies on New Guidance—Can It Keep Going? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
